ATE478686T1 - Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten - Google Patents

Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten

Info

Publication number
ATE478686T1
ATE478686T1 AT98932549T AT98932549T ATE478686T1 AT E478686 T1 ATE478686 T1 AT E478686T1 AT 98932549 T AT98932549 T AT 98932549T AT 98932549 T AT98932549 T AT 98932549T AT E478686 T1 ATE478686 T1 AT E478686T1
Authority
AT
Austria
Prior art keywords
wilms
medications
tumors containing
tumor expression
containing inhibitors
Prior art date
Application number
AT98932549T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama filed Critical Haruo Sugiyama
Application granted granted Critical
Publication of ATE478686T1 publication Critical patent/ATE478686T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98932549T 1997-07-16 1998-07-16 Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten ATE478686T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19163597A JP4789095B2 (ja) 1997-07-16 1997-07-16 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
PCT/JP1998/003198 WO1999003506A1 (en) 1997-07-16 1998-07-16 Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors

Publications (1)

Publication Number Publication Date
ATE478686T1 true ATE478686T1 (de) 2010-09-15

Family

ID=16277943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98932549T ATE478686T1 (de) 1997-07-16 1998-07-16 Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten

Country Status (7)

Country Link
US (1) US7696180B2 (de)
EP (1) EP1004319B1 (de)
JP (1) JP4789095B2 (de)
AT (1) ATE478686T1 (de)
AU (1) AU8243198A (de)
DE (1) DE69841858D1 (de)
WO (1) WO1999003506A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103564B1 (de) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2002006297A1 (en) * 2000-07-19 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Novel antisense oligonucleotide derivatives against wilms's tumor gene
BRPI0208183B8 (pt) 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
EP1738772A4 (de) * 2004-03-29 2007-12-26 Haruo Sugiyama Mikro-rna zur hemmung der expression des wt1-gens und ihre verwendung
JP5165890B2 (ja) 2004-03-29 2013-03-21 治夫 杉山 ＷＴ１遺伝子の発現を抑制するｓｉＲＮＡおよびその利用
EP1741786A4 (de) * 2004-03-29 2007-05-09 Haruo Sugiyama Verfahren zur trennung von vorläuferzellen von leberzellen, endothelzellen oder hämatopoetischen zellen von zellmasse
JP4986816B2 (ja) * 2007-11-09 2012-07-25 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
CA2940962C (en) 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
NL1000453C2 (nl) 1995-05-30 1996-12-03 Boer Beheer Nijmegen Bv De Inrichting voor het vervaardigen van vormlingen uit klei voor de produktie van stenen.
AU5779696A (en) * 1995-06-01 1996-12-18 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
JP3904260B2 (ja) * 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
KR100262838B1 (ko) * 1996-04-16 2003-03-15 기시모토 다다미쓰 고형암세포및조직이형성의검출방법,및골수이식및말초혈간세포이식용조직의검사방법

Also Published As

Publication number Publication date
US7696180B2 (en) 2010-04-13
DE69841858D1 (de) 2010-10-07
EP1004319A4 (de) 2005-08-10
AU8243198A (en) 1999-02-10
JP4789095B2 (ja) 2011-10-05
EP1004319A1 (de) 2000-05-31
WO1999003506A1 (en) 1999-01-28
EP1004319B1 (de) 2010-08-25
US20060105981A1 (en) 2006-05-18
JPH1135484A (ja) 1999-02-09

Similar Documents

Publication Publication Date Title
ATE478686T1 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
FR2722506B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
DE69535684D1 (de) Zusammensetzungen welche DNA zerstoerende Agentien und P53 enthalten
ES2141393T3 (es) Uso de oligonucleotidos sustituidos en posicion 2' para regulacion supresora de la expresion genica.
CA2265917A1 (en) Method for using oligonucleotides having modified cpg dinucleosides
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
TR199800019T1 (xx) Trombosit topaklanmas�n� �nleyici yeni maddeler.
CA2229171A1 (en) Method of modulating gene expression with reduced immunostimulatory response
EP0735046A4 (de) Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält
BG104780A (en) Inhibitors of phospholipase enzymes
DK1019428T3 (da) Inverterede kimæriske og hybride oligonucleotider
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
ZA905312B (en) Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia
PT946166E (pt) Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
BG105361A (en) Genes of the 1-desoxy-d-xylulose biosynthetic pathway
BRPI0410663A (pt) compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
ATE162721T1 (de) Neue sonde zur tumordiagnostik oder tumortherapie
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
DE69332375D1 (de) Hundecoronavirus s gen und verwendung davon
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
ATE384133T1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
EP1086116A4 (de) Zusammensetzungen und verfahren für den pulmonativen transport von nuklein-säuren
TR199902564T2 (xx) K�k�rdak oligomer matris proteininin romatoid artrit tedavisinde kullan�m�.
GEP20012440B (en) Biphenylsulfonamide Matrix Metalloproteinase Inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties